Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2022 before the market opens on Wednesday, February 1, 2023, and will hold a conference call on the same day at 8:30 a.m. EST.
During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 982319. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under “Earnings Results.” A replay of the call will be available under “News and Events” through Friday, February 17, 2023.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Last Trade: | US$528.89 |
Daily Change: | -5.79 -1.08 |
Daily Volume: | 597,875 |
Market Cap: | US$199.710B |
July 16, 2025 May 06, 2025 April 23, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load